Uğur Şahin, BioNTech CEO (Sebastian Gollnow/picture-alliance/dpa/AP Images)
October 2, 2024 03:48 PM EDTUpdated October 3, 07:42 AM
R&D
AI

BioN­Tech opens the hood on its AI am­bi­tions, and they're not just for mR­NA

Ryan Cross

Senior Science Correspondent

BioN­Tech be­came a big name in bio­phar­ma thanks to its Pfiz­er-part­nered Covid-19 vac­cine. It’s bet­ting that ar­ti­fi­cial in­tel­li­gence will be key to its fu­ture. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Take­da to pay $200M for rights to ane­mia drug from Keros

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Rev­o­lu­tion sells $600M in shares on back of RAS in­hibitor port­fo­lio up­dates

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

Gilead makes an­oth­er ADC move, ink­ing up to $415M pact with Tubu­lis

A service from the Financial Times